



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

### Unaudited Financial Results for the Quarter/year ended 30.06.2009

Particulars	(Rs. in lacs)		
	Quarter ended 30.06.2009 Unaudited	Quarter ended 30.06.2008 Unaudited	12 Months ended 31.03.2009 Audited
1 Net sales/Income from Operations	3330.12	3037.14	13619.76
2 Other income			27.06
3 Total Income (1+2)	3330.12	3037.14	13646.82
4 Expenditure			
a. (Inc.)/Dec. in Stock in trade and work in progress	-120.69	514.11	787.24
b. Consumption of Raw Materials	1575.08	1060.59	6338.40
c. Purchase of traded goods	423.17	49.09	764.68
d. Employees Cost	516.24	476.38	1969.07
e. Depreciation	49.78	40.36	124.98
f. Other Expenditure	599.39	655.75	2214.67
g. Total	3042.97	2796.28	12199.04
5 Interest	97.00	120.71	457.93
6 Exceptional Items			
7 Profit(+)/Loss(-) from Ordinary Activities before tax (3) - (4+5+6)	190.15	120.15	989.85
8 Tax expense	40.00	50.00	372.62
9 Net Profit(+)/Loss(-) from Ordinary Activities after tax (7-8)	150.15	70.15	617.23
10 Extraordinary Items (net of tax expense)			
11 Net Profit (+)/ Loss (-) for the period (9-10)	150.15	70.15	617.23
12 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90
13 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.			5277.85
14 Earnings Per Share (EPS)			
a. Basic & diluted EPS before extraordinary items for the period.	0.57	0.27	2.36
b. Basic & diluted EPS after extraordinary items for the period.	0.57	0.27	2.36
15 Public shareholding :			
- Number of shares	8962320	8962320	8962320
- Percentage of Shareholding	34.21%	34.21%	34.21%

#### Notes

- The Financial Results for the Quarter ended 30.06.2009 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 29.07.2009
- No complaints were pending at the beginning/end of the quarter ended 30.06.2009. However 38 requests for change of address/ dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

By Order of the Board  
For Jagsonpal Pharmaceutical

Rajpal Singh Kochhar  
Managing Director

Place : New Delhi  
Date : 29.07.2009